Vietnam-based Gene Solutions, a provider of genetic tests and non-invasive prenatal testing (NIPT) for women’s health and oncology, has partnered with China’s Topgen Biopharm Co., Ltd., a specialist in tumor precision medicine. The collaboration aims to enhance clinical validation, translational research, and co-commercialization efforts, thereby improving cancer treatment outcomes and health management standards across the region.
Collaboration Details
Through this partnership, Gene Solutions will introduce several advanced oncology solutions to expand precision medicine capabilities. These include SPOT-MAS, Asia’s first clinically validated multi-cancer early detection (MCED) blood test; SPOT-MAS Lung, a precision lung cancer early screening solution; and K-4CARE, a ctDNA-based minimal residual disease (MRD) monitoring technology. These innovations will enrich Topgen Bio’s oncology testing portfolio.
Topgen Bio’s Platform and Reach
Topgen Bio operates a comprehensive next-generation sequencing (NGS) platform, serving over 1,300 hospitals nationwide. The collaboration will equip its hospital network with cutting-edge cancer screening and monitoring tools, accelerating the adoption of early cancer detection and management solutions.-Fineline Info & Tech
